Association between atrial fibrillation and patient-important outcomes in heart failure patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 02 10 2018
revised: 12 11 2018
accepted: 19 11 2018
pubmed: 22 11 2018
medline: 22 5 2019
entrez: 22 11 2018
Statut: ppublish

Résumé

To assess the association between atrial fibrillation (AF) and all-cause mortality and implantable cardioverter-defibrillators (ICDs) therapies in heart failure (HF) patients with reduced ejection fraction and an ICD implanted. A systematic MEDLINE search performed from inception through November 2016, supplemented by hand searching of reference lists, identified 62 eligible studies (227 998 patients) reporting on the association between AF and outcomes in HF patients; 36 studies included data on all-cause mortality, 30 on appropriate, and 17 on inappropriate ICD interventions. Hazard ratio, risk ratio, or odds ratio estimates were used based on data availability. Effect estimates were synthesized under a random-effects model. Implantable cardioverter-defibrillator-implanted HF patients with a history of AF had a 42% {combined effect estimate (cEE) 1.42 [95% confidence interval (CI) 1.28-1.57]} higher risk of all-cause mortality compared with patients with no AF history. Furthermore, AF patients had a higher risk of appropriate [cEE 1.44 (95% CI 1.27-1.64)] and inappropriate ICD interventions [cEE 2.05 (95% CI 1.75-2.44)]. Atrial fibrillation history is statistically significantly associated with adverse major clinical outcomes in ICD-implanted HF patients. Patients with AF have a higher risk of all-cause mortality, appropriate, and inappropriate ICD interventions compared with patients with no AF history. Whether AF may have an independent deleterious effect on HF prognosis or may simply be a marker of HF severity should be further investigated.

Identifiants

pubmed: 30462233
pii: 5194686
doi: 10.1093/ehjqcco/qcy054
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-104

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Auteurs

Katerina K Naka (KK)

2nd Department of Cardiology, University of Ioannina Medical School, University Campus, Ioannina, Greece.

George Bazoukis (G)

Department of Cardiology, Catheterization Laboratory, Evangelismos General Hospital of Athens, Ipsilantou 45-47, Athens, Greece.

Aris Bechlioulis (A)

2nd Department of Cardiology, University of Ioannina Medical School, University Campus, Ioannina, Greece.

Panagiotis Korantzopoulos (P)

1st Department of Cardiology, University of Ioannina Medical School, University Campus, Ioannina, Greece.

Lampros K Michalis (LK)

2nd Department of Cardiology, University of Ioannina Medical School, University Campus, Ioannina, Greece.

Evangelia E Ntzani (EE)

Department of Hygiene and Epidemiology, University of Ioannina Medical School, University Campus, Ioannina, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH